Journal ArticleOPEN ACCESS

Bevacizumab for Brain Radiation Necrosis in Patients With Nonsquamous Nonsmall Cell Lung Cancer

Clinical Lung Cancer (2024) 25(6) 581-586.e3
DOI: 10.1016/j.cllc.2024.06.010
4Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The incidence of brain radiation necrosis is increasing in NSCLC patients undergoing radiotherapy for brain metastases. • [11C] methionine–PET and MRS are valuable tools for diagnosing brain radiation necrosis. • Bevacizumab is an effective treatment for brain radiation necrosis in patients with nonsquamous NSCLC.

Author supplied keywords

Cite

CITATION STYLE

APA

Shibahara, D., Tanaka, K., Togao, O., Shiraishi, Y., Yoneshima, Y., Iwama, E., … Okamoto, I. (2024). Bevacizumab for Brain Radiation Necrosis in Patients With Nonsquamous Nonsmall Cell Lung Cancer. Clinical Lung Cancer, 25(6), 581-586.e3. https://doi.org/10.1016/j.cllc.2024.06.010

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free